Decreased levels of homoarginine and asymmetric dimethylarginine in children with type 1 diabetes: Associations with cardiovascular risk factors but no effect by atorvastin

Journal of Pediatric Endocrinology and Metabolism

Volumn 28, Issue 1-2, 2015, Pages 147-152

  Krebs, Andreas ^a   Doerfer, Jürgen ^a   Grünert, Sarah Catherina ^a   Wöhrl, Jan ^a   Stier, Bernhard ^b   Schmidt Trucksäss, Arno ^c   Lichte, Kai ^d   Winkler, Karl ^a   Grulich Henn, Jürgen ^e   Holder, Martin ^d   Schwab, Karl Otfried ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Practice for Pediatrics and Adolescent Medicine   (Germany)

^c UNIVERSITY OF BASEL   (Switzerland)

^d Institute of Exercise and Health Sciences Department Sports Medicine University of Basel ^*  (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

ADMA; atorvastatin; homoarginine; pediatric type 1 diabetes

Indexed keywords

ATORVASTATIN; HEMOGLOBIN A1C; HOMOARGININE; N(G),N(G) DIMETHYLARGININE; PLACEBO; ARGININE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; HEPTANOIC ACID DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; LIPID; N,N-DIMETHYLARGININE; PYRROLE DERIVATIVE;

ADOLESCENT; ARTICLE; CARDIOVASCULAR RISK; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PULSE PRESSURE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SYSTOLIC BLOOD PRESSURE; ANALOGS AND DERIVATIVES; BLOOD; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; FOLLOW UP; METABOLISM; PILOT STUDY; RISK FACTOR; TREATMENT OUTCOME;

ADOLESCENT; ANTICHOLESTEREMIC AGENTS; ARGININE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 1; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HEPTANOIC ACIDS; HOMOARGININE; HUMANS; LIPIDS; MALE; PILOT PROJECTS; PYRROLES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84920095157     PISSN: 0334018X     EISSN: 21910251     Source Type: Journal    
DOI: 10.1515/jpem-2014-0083     Document Type: Article

References (30)

1. Ryan WL, Wells IC. Homocitrulline and homoarginine synthesis from lysine. Science 1964; 144: 1122-7.
2. Atzler D, Mieth M, Maas R, Boger RH, Schwedhelm E. Stable isotope dilution assay for liquid chromatography-tandem mass spectrometric determination of L-homoarginine in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2011; 879: 2294-8.
3. Davids M, Ndika JD, Salomons GS, Blom HJ, Teerlink T. Promiscuous activity of arginine: glycine amidinotransferase is responsible for the synthesis of the novel cardiovascular risk factor homoarginine. FEBS Lett 2012; 586: 3653-7.
4. Chatterjee A, Catravas JD. Endothelial nitric oxide (NO) and its pathophysiologic regulation. Vascul Pharmacol 2008; 49: 134-40.
5. Marz, W, Meinitzer A, Drechsler C, Pilz S, Krane V, et al. Homoarginine, cardiovascular risk, and mortality. Circulation 2010; 122: 967-75.
6. Drechsler C, Meinitzer A, Pilz A, Krane V, Tomaschitz A, et al. Homoarginine, heart failure, and sudden cardiac death in hemodialysis patients. Eur J Heart Fail 2011; 13: 852-9.
7. Krebs A, Schmidt-Trucksass A, Doerfer, Grulich-Henn J, Holder M, et al. Cardiovascular risk in pediatric type 1 diabetes: sex-specific intima-media thickening verified by automatic contour identification and analyzing systems. Pediatr Diabetes 2012; 13: 251-8.
8. Schwab KO, Doerfer J, Hecker W, Grulich-Henn J, Wiemann D, et al. On behalf of the DPV initiative of the German Working Group for Pediatric Diabetology. Spectrum and prevalence of atherogenic risk factors in 27,358 children, adolescents, and young adults with type 1 diabetes. Cross-sectional data from the German diabetes documentation and quality management system (DPV). Diabetes Care 2006; 29: 218-25.
9. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol 2004; 24: 1023-30.
10. Boger RH. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials. Vasc Med 2005; 10: S19-25.
11. Maas R, Xanthakis V, Polak JF, Schwedhelm E, Sullivan LM, et al. Association of the endogenous nitirc oxide synthase inhibitor ADMA with carotid artery intima media thickness in the Framingham Heart Study Offspring Cohort. Stroke 2009; 40: 2715-9.
12. Anderssohn M, Schwedhelm E, Luneburg N, Vasan RS, Boger RH. Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: an intriguing interaction with diabetes mellitus. Diab Vasc Dis Res 2010; 7: 105-18.
13. Huemer M, Simma B, Mayr D, Muhl A, Rami B, et al. Low levels of asymmetric dimethylarginine in children with diabetes mellitus type I compared with healthy children. J Pediatr 2011; 158: 602-6.
14. Valkonen V-P, Laakso J, Paiva H, Lehtimaki T, Lakka TA, et al. Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels? Arterioscler Suppl 2003; 4: 19-22.
15. Nishiyama Y, Ueda M, Otsuka T, Katsura K, Abe A, et al. Statin treatment decreased serum asymmetric dimethylarginine (ADMA) levels in ischemic stroke patients. J Atheroscler Thromb 2011; 18: 131-7.
16. Silverstein J, Klingensmith G, Copeland K, Plotnick L, Kaufman F, et al. Care of children and adolescents with type 1 diabetes. Diabetes Care 2005; 28: 186-212.
17. Kromeyer-Hauschild K, Wabitsch M, Kunze D, et al. Percentiles of body mass index in children and adolescents evaluated from different regional German studies. Monatsschr Kinderheilkd 2001; 149: 807-18.
18. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
19. Martens-Lobenhoffer J, Bode-Boger SM. Quantification of L-arginine, asymmetric dimethylarginine and symmetric dimethylarginine in human plasma: a step improvement in precision by stable isotope dilution mass spectrometry. J Chromatogr B 2012; 904: 140-3.
20. Versari D, Daghini E, Virdis A, Ghiadoni L, Taddei S. Endothelial dysfunction as a target for prevention of cardiovascular disease. Diabetes Care 2009; 32: S314-21.
21. Henningsson R, Lundquist I. Arginine-induced insulin release is decreased and glucagon increased in parallel with islet NO production. Am J Physiol 1998; 275: E500-6.
22. Jaźwińska-Kozuba A, Martens-Lobenhoffer J, Kruszelnicka O, Rycaj J, Chyrchel B, et al. Opposite associations of plasma homoarginine and ornithine with arginine in healthy children and adolescents. Int J Mol Sci 2013; 14: 21819-32.
23. Jarvisalo MJ, Raitakari M, Toikka JO, Putto-Laurila A, Rontu R, et al. Endothelial dysfunction and increased arterial intimamedia thickness in children with type 1 diabetes. Circulation 2004; 109: 1750-5.
24. Ceriello A, Esposito K, Ihnat M, Thorpe J, Giugliano D. Long-term glycemic control influences the long-lasting effectof hyperglycemia on endothelial function in type 1 diabetes. J Clin Endocrinol Metab 2009; 94: 2751-6.
25. West MB, Ramana KV, Kaiserova K, Srivastava SK, Bhatnagar A. L-arginine prevents metabolic effects of high glucose in diabetic mice. FEBS Lett 2008; 582: 2609-14.
26. Eid HM, Lyberg T, Arnesen H, Seljeflot I. Insulin and adiponectin inhibit the TNFá-induced ADMA accumulation in human endothelial cells: the role of DDAH. Atherosclerosis 2007; 194: e1-8.
27. Eid HM, Reims H, Arnesen H, Kjeldsen SE, Lyberg, T, et al. Decreased levels of asymmetric dimethylarginine during acute hyperinsulinemia. Metab Clin Exp 2007; 56: 464-9.
28. Marcoveccio ML, Widmer B, Dunger DB, Dalton RN. Effect of acute variations of insulin and glucose on plasma concentrations of asymmetric dimethylarginine in young people with type 1 diabetes. Clin Sci (Lond) 2008; 115: 361-9.
29. Haller MJ, Stein JM, Shuster JJ, Theriaque D, Samyn MM, et al. Pediatric Atorvastatin in Diabetes Trial (PADIT): a pilot study to determine the effect of atorvastatin on arterial stiffness and endothelial function in children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2009; 22: 65-8.
30. Beltowski J, Kedra A. Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy. Pharmacol Rep 2006; 58: 159-78.